How to Get CagriSema Online in Milan
CagriSema is an experimental treatment not yet approved for weight loss in the EU and is not offered by Hi-Doctor. This article explains its regulatory status and offers insights into proven, EU-approved weight-loss treatments.

DIRECT ANSWER
An online consultation lets an EU-licensed doctor review your case and, if appropriate, issue a prescription that is valid across the EU.
Less than 4 hours on average
Prescription issued in less than 4 hours on average if approved.
EU-licensed doctors
Every case is reviewed by a licensed clinician.
Valid across the EU
Approved prescriptions can be used at any EU pharmacy.
In this article
If you're searching for CagriSema online in Milan, Italy, it's important to know that this medication is currently not approved for weight-loss prescription in the EU. This means it is not legally available through pharmacies in Italy or any other EU country, and Hi-Doctor does not currently prescribe or offer it. CagriSema is still in clinical trials, and its journey to market authorization is ongoing. However, your interest in advanced weight-loss solutions is understandable. Here's what CagriSema actually is, why it isn't a normal option yet, and what proven, EU-approved weight-loss treatments you CAN get today from an EU-licensed doctor through Hi-Doctor.
What is CagriSema, and why isn't it a normal option yet?
CagriSema is an investigational drug developed by Novo Nordisk for weight management. It's a combination of two active compounds: semaglutide (a GLP-1 receptor agonist, found in Ozempic and Wegovy) and cagrilintide (an amylin analog). This combination aims to provide a triple-action effect by targeting GLP-1, GIP, and glucagon receptors, which are involved in appetite regulation, food intake, and glucose metabolism. While early clinical trial results have shown promising weight loss, CagriSema has not yet received market authorization from the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA). This means it is not considered a standard, approved medical treatment and is only accessible within tightly controlled clinical study environments. Attempting to purchase CagriSema from unregulated online sources carries significant safety risks, as these products may be counterfeit, contaminated, or incorrectly dosed, with no medical oversight.
Proven weight-loss medications available online today
While CagriSema is not yet available, several highly effective and EMA-approved medications are prescribed by EU-licensed doctors for weight management today. These treatments have undergone rigorous testing and are proven to be safe and effective when used under medical supervision:
- Ozempic (semaglutide): Primarily approved for type 2 diabetes, it's also prescribed off-label for weight management due to its significant appetite-suppressing effects. It's suitable for patients with a high BMI and/or obesity-related comorbidities.
- Wegovy (semaglutide): This is a higher-dose formulation of semaglutide, specifically approved and indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
- Mounjaro (tirzepatide): Approved for type 2 diabetes, tirzepatide is a dual GIP and GLP-1 receptor agonist that has shown substantial weight loss in clinical trials, making it another option considered off-label for weight management by doctors.
- Saxenda (liraglutide): A daily GLP-1 receptor agonist approved for weight management, Saxenda is often prescribed for individuals who may not tolerate semaglutide or prefer a daily injection regimen.
How to get a weight-loss prescription online in Milan, Italy
Getting a prescription for approved weight-loss medication through Hi-Doctor is a straightforward and secure process, valid for use in Milan or anywhere in the EU:
- Complete an Online Questionnaire: Spend 2–3 minutes filling out a comprehensive medical questionnaire about your health, medical history, and weight-loss goals.
- EU-Licensed Doctor Review: An EU-licensed doctor will meticulously review your case to determine if medication is appropriate and safe for you.
- REMPE Prescription in <24 h: If approved, you'll receive a REMPE electronic prescription (Spanish standard, valid EU-wide) as a downloadable PDF in your account and via email, typically within 24 hours. The online consultation costs a flat €25, and if the doctor finds treatment isn't appropriate, this fee is automatically refunded.
- Pick Up at Any EU Pharmacy: Present your prescription at any pharmacy in Milan or any other EU country, either by printing it or showing it on your phone, thanks to cross-border prescription directive 2011/24/EU.
Why choose Hi-Doctor over unregulated peptide sellers
When it comes to your health, choosing a regulated, medically sound path is paramount. Hi-Doctor offers a safe, legal, and effective alternative to unregulated peptide sellers:
- EU-Licensed Doctors: Our platform connects you with real, EU-licensed doctors who provide individual case reviews and medical oversight, ensuring prescriptions are appropriate for your specific health needs.
- Real, Approved Medications: We only facilitate access to EMA-approved medications, ensuring safety, efficacy, and traceability.
- Secure & Compliant: All interactions occur within your private, RGPD-compliant account, ensuring your data's privacy and security.
- Trusted by Thousands: With over 50,000 patients served and a 4.8 Trustpilot rating, Hi-Doctor is a trusted name in online medical consultations.
- Transparency & Support: Unlike 'research chemicals' or grey-market vendors, our process is transparent, auditable, and supported by professional medical staff.
Hi-Doctor is continuously onboarding new EU-licensed specialists across new conditions. If a specific treatment isn't covered today, patients can register interest at hi-doctor.ai and be notified when a doctor becomes available.
COMMON QUESTIONS
Frequently asked questions
No, Cagrisema is not legal to buy online or in pharmacies in Spain or any other EU country, as it has not yet received market authorization from the European Medicines Agency.
